Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis
Morie A. Gertz, MD, chair, General Internal Medicine, Mayo Clinic Comprehensive Cancer Center, discusses the rationale for the phase 3 AFFIRM-AL trial (NCT04973137) in patients with amyloid light chain (AL) amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
myBinderRelated Content
-
FDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated AmyloidosisThe FDA announced that it has approved p...
-
Stephen J. Kennel, PhDStephen J. Kennel is Professor at The Un...
-
ISA Virtual Workshop on Gaps in Diagnosis and Management of AL Amyloidosishttps://vimeo.com/645401404...
-
The Judy and Bernard Briskin Center for Multiple Myeloma Research, City of HopeCity of Hope is committed to beating thi...
-
Alnylam Reports Positive Topline 18-Month Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR A...Alnylam Pharmaceuticals, Inc., the leadi...
-
Future AL Amyloidosis Treatmenthttps://www.youtube.com/watch?v=K25lurau...
-
Emily Martin, PhDEmily Martin is an Associate professor a...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
